-
Mashup Score: 1
The European Commission has approved idecabtagene vicleucel for triple-class–exposed relapsed/refractory multiple myeloma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Triple-Class-Exposed Myeloma: Study Explores Outcomes With Subsequent Lines of Therapy | Cancer Nursing Today - 1 day(s) ago
Triple-class-exposed multiple myeloma occurs when a patient has received at least 1 immunomodulatory drug, at least 1 proteasome, and at 1 least one anti-CD38 monoclonal antibody.
Source: cancernursingtoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 7
Brea C. Lipe, MD, is a professor of medicine and clinical director of the multiple myeloma program at the James P. Wilmot Cancer Center of the University of Rochester Medical Center in New York. I have always loved the words and stories contained within books. I would even say that my love of books has propelled much of my success in life, serving as an escape, inspiration, reimagination, or education. I make a conscious effort to honor this personal legacy by continued reading and reflecting on stories
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet-
Very nice @ASH_hematology @ASHClinicalNews editorial by Dr. Lipe about the nuances in our words in oncology. Many absolutely perceive immunoTx to be milder than chemo - I often talk about 'targeted Tx' in #MMsm, which also sound mild but have real AEs! https://t.co/jBOT9gRKmi https://t.co/XfYXRWmEyY
-
-
Mashup Score: 101Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma - 6 day(s) ago
Click on the article title to read more.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Partners & KOLsTweet-
Our paper on natural history, mode of progression, and discordance between risk-stratification models in ~100 consecutive patients with Smoldering Myeloma diagnosed since 2014 @columbiacancer (led by @Slade_Mellgard)- Now out in @Hemasphere_EHA! #mmsm 🧵 https://t.co/nz5RrtjWS6 https://t.co/VvHYMgFxRI
-
-
Mashup Score: 3Functional Status Associations With Treatment Receipt and Outcomes Among Older Adults Newly Diagnosed With Multiple Myeloma - 6 day(s) ago
PURPOSE Multiple myeloma (MM) is a prevalent hematologic malignancy in older adults, who often experience physical disability, increased health care usage, and reduced treatment tolerance. Home health (HH) services are frequently used by this group, but the relationship between disability, HH use, and MM treatment receipt is unclear. This study examines the connections between disability, treatment receipt, and survival outcomes in older adults with newly diagnosed MM using a nationwide data set. METHODS The SEER-Medicare data set was used to identify adults aged 66 years and older diagnosed with MM from 2010 to 2017, who used HH services the year before diagnosis. Disability was assessed with the Outcome and Assessment Information Set, using a composite score derived from items related to ability to complete activities of daily living. Mortality, therapy receipt, and health care utilization patterns were evaluated. RESULTS Of 37,280 older adults with MM, 6,850 (18.2%) used HH services
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis - 6 day(s) ago
Blood Cancer Journal – Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
Source: www.nature.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 8Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis - 6 day(s) ago
Blood Cancer Journal – Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
Source: www.nature.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 96Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma - 7 day(s) ago
Click on the article title to read more.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Partners & KOLsTweet-
Our paper on natural history, mode of progression, and discordance between risk-stratification models in ~100 consecutive patients with Smoldering Myeloma diagnosed since 2014 @columbiacancer (led by @Slade_Mellgard)- Now out in @Hemasphere_EHA! #mmsm 🧵 https://t.co/nz5RrtjWS6 https://t.co/VvHYMgFxRI
-
-
Mashup Score: 2Relapsed/Refractory Multiple Myeloma Overview - 7 day(s) ago
Binod Dhakal, MD, provides a high-level overview of relapsed/refractory multiple myeloma (R/R MM), including the clinical hallmarks, risk factors, and patient stratification.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
Ide-Cel Receives EU Approval for Triple Class–Exposed R/R Multiple Myeloma @paurotero @ClinicaNavarra @EU_Commission #mmsm https://t.co/RdFtHmWn3u